Cite
Cabozantinib in combination with immune checkpoint inhibitors for renal cell carcinoma: a systematic review and meta-analysis.
MLA
Su, Jingyang, et al. “Cabozantinib in Combination with Immune Checkpoint Inhibitors for Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.” Frontiers in Pharmacology, vol. 15, Apr. 2024, p. 1322473. EBSCOhost, https://doi.org/10.3389/fphar.2024.1322473.
APA
Su, J., Zhang, J., Wu, Y., Ni, C., Ding, Y., Cai, Z., Xu, M., Lai, M., Wang, J., Lin, S., & Lu, J. (2024). Cabozantinib in combination with immune checkpoint inhibitors for renal cell carcinoma: a systematic review and meta-analysis. Frontiers in Pharmacology, 15, 1322473. https://doi.org/10.3389/fphar.2024.1322473
Chicago
Su, Jingyang, Jialin Zhang, Yuqian Wu, Cui Ni, Yueyue Ding, Zelin Cai, Ming Xu, et al. 2024. “Cabozantinib in Combination with Immune Checkpoint Inhibitors for Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.” Frontiers in Pharmacology 15 (April): 1322473. doi:10.3389/fphar.2024.1322473.